186 related articles for article (PubMed ID: 9593551)
1. Mycophenolate mofetil in cardiac transplantation.
Kobashigawa JA
Curr Opin Cardiol; 1998 Mar; 13(2):117-21. PubMed ID: 9593551
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
4. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection.
Klupp J; van Gelder T; Dambrin C; Regieli JJ; Boeke K; Billingham ME; Morris RE
J Heart Lung Transplant; 2004 Mar; 23(3):334-51. PubMed ID: 15019644
[TBL] [Abstract][Full Text] [Related]
5. Individualization of mycophenolate mofetil dose in renal transplant recipients.
van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
Fulton B; Markham A
Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil.
Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
[TBL] [Abstract][Full Text] [Related]
8. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil.
Lehmkuhl H; Hummel M; Kobashigawa J; Ladenburger S; Rothenburger M; Sack F; Dengler T; Hetzer R
Transplant Proc; 2008 May; 40(4):953-5. PubMed ID: 18555088
[TBL] [Abstract][Full Text] [Related]
9. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.
Kobashigawa J; Miller L; Renlund D; Mentzer R; Alderman E; Bourge R; Costanzo M; Eisen H; Dureau G; Ratkovec R; Hummel M; Ipe D; Johnson J; Keogh A; Mamelok R; Mancini D; Smart F; Valantine H
Transplantation; 1998 Aug; 66(4):507-15. PubMed ID: 9734496
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment.
Renlund DG; Gopinathan SK; Kfoury AG; Taylor DO
Clin Transplant; 1996 Feb; 10(1 Pt 2):136-9. PubMed ID: 8680051
[TBL] [Abstract][Full Text] [Related]
11. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation.
Kobashigawa JA; Meiser BM
Transplantation; 2005 Oct; 80(2 Suppl):S235-43. PubMed ID: 16251856
[TBL] [Abstract][Full Text] [Related]
12. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
Halloran P; Mathew T; Tomlanovich S; Groth C; Hooftman L; Barker C
Transplantation; 1997 Jan; 63(1):39-47. PubMed ID: 9000658
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.
Taylor DO; Ensley RD; Olsen SL; Dunn D; Renlund DG
J Heart Lung Transplant; 1994; 13(4):571-82. PubMed ID: 7947873
[TBL] [Abstract][Full Text] [Related]
16. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
Behrend M
Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
18. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
[TBL] [Abstract][Full Text] [Related]
19. [Use of mycophenolate mofetil in kidney transplantation].
Hrvacevic R; Ignjatovic Lj; Vavic N
Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil--a new immunosuppressant for organ transplantation.
Med Lett Drugs Ther; 1995 Sep; 37(958):84-6. PubMed ID: 7674993
[No Abstract] [Full Text] [Related]
[Next] [New Search]
